FI105548B - Menetelmä farmaseuttisesti aktiivisten 1,3-dihydro-2H-imidatso(4,5-b)kinolin-2-onien valmistamiseksi - Google Patents

Menetelmä farmaseuttisesti aktiivisten 1,3-dihydro-2H-imidatso(4,5-b)kinolin-2-onien valmistamiseksi Download PDF

Info

Publication number
FI105548B
FI105548B FI942010A FI942010A FI105548B FI 105548 B FI105548 B FI 105548B FI 942010 A FI942010 A FI 942010A FI 942010 A FI942010 A FI 942010A FI 105548 B FI105548 B FI 105548B
Authority
FI
Finland
Prior art keywords
formula
alkyl
optionally substituted
dihydro
amino
Prior art date
Application number
FI942010A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942010A (fi
FI942010A0 (fi
Inventor
Eddy Jean Edgard Freyne
Chaffoy De Courcelles Didie De
Alfons Herman Raeymaekers
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI942010A publication Critical patent/FI942010A/fi
Publication of FI942010A0 publication Critical patent/FI942010A0/fi
Application granted granted Critical
Publication of FI105548B publication Critical patent/FI105548B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
FI942010A 1991-10-30 1994-04-29 Menetelmä farmaseuttisesti aktiivisten 1,3-dihydro-2H-imidatso(4,5-b)kinolin-2-onien valmistamiseksi FI105548B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78495591A 1991-10-30 1991-10-30
US78495591 1991-10-30
EP9202496 1992-10-27
PCT/EP1992/002496 WO1993009118A1 (en) 1991-10-30 1992-10-27 1,3-dihydro-2h-imidazo(4,5-b)quinolin-2-one derivatives as phosphodiesterase inhibitors

Publications (3)

Publication Number Publication Date
FI942010A FI942010A (fi) 1994-04-29
FI942010A0 FI942010A0 (fi) 1994-04-29
FI105548B true FI105548B (fi) 2000-09-15

Family

ID=25134048

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942010A FI105548B (fi) 1991-10-30 1994-04-29 Menetelmä farmaseuttisesti aktiivisten 1,3-dihydro-2H-imidatso(4,5-b)kinolin-2-onien valmistamiseksi

Country Status (24)

Country Link
US (3) US5521187A (xx)
EP (2) EP0610372B1 (xx)
JP (1) JP3488922B2 (xx)
KR (1) KR100251895B1 (xx)
CN (1) CN1041726C (xx)
AT (1) ATE131479T1 (xx)
AU (1) AU660337B2 (xx)
CA (1) CA2121230C (xx)
DE (1) DE69206820T2 (xx)
DK (1) DK0610372T3 (xx)
ES (1) ES2083773T3 (xx)
FI (1) FI105548B (xx)
GR (1) GR3018909T3 (xx)
HU (1) HU220608B1 (xx)
IL (1) IL103570A (xx)
MX (1) MX9206258A (xx)
NO (1) NO300976B1 (xx)
NZ (1) NZ244779A (xx)
PH (1) PH31245A (xx)
PL (1) PL170749B1 (xx)
RU (1) RU2127273C1 (xx)
TW (1) TW249234B (xx)
WO (1) WO1993009118A1 (xx)
ZA (1) ZA928373B (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5502177A (en) * 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5703827A (en) * 1996-02-29 1997-12-30 Monolithic System Technology, Inc. Method and structure for generating a boosted word line voltage and a back bias voltage for a memory array
US6007992A (en) * 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
EP1332133B1 (en) * 2000-10-02 2008-07-09 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
PL218788B1 (pl) * 2002-03-29 2015-01-30 Janssen Pharmaceutica Nv Znakowane radioaktywnie pochodne chinoliny i jej zastosowanie
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
CA2535117A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1660026A4 (en) 2003-09-05 2008-07-16 3M Innovative Properties Co TREATMENT FOR CD5 + B CELL LYMPHOMA
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AU2004291122A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
WO2006083440A2 (en) 2004-12-30 2006-08-10 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
EP1844201B1 (en) 2005-02-04 2016-08-24 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ,インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての1−置換ピラゾロ(3,4−c)環状化合物
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ,インコーポレイテッド ピラゾロピリジン−1,4−ジアミン、およびそのアナログ
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EP1969929A1 (de) * 2007-03-12 2008-09-17 Bayer CropScience AG Substituierte Phenylamidine und deren Verwendung als Fungizide
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014055586A1 (en) 2012-10-02 2014-04-10 California Institute Of Technology Transition-metal free reductive cleavage of aromatic c-o, c-n, and c-s bonds by activated silanes
RU2651570C2 (ru) 2012-10-02 2018-04-23 Кэлифорниа Инститьют Оф Текнолоджи Силилирование ароматических соединений без переходных металлов
US9809607B2 (en) 2014-08-06 2017-11-07 California Institute Of Technology Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts
EP3189063B1 (en) 2014-09-02 2019-08-14 California Institute of Technology Base-catalyzed silylation of terminial alkyne c-h bonds
WO2016100606A1 (en) 2014-12-19 2016-06-23 California Institute Of Technology Silylation of aromatic heterocycles by disilanes using potassium alkoxide catalysts
CN110441434A (zh) * 2019-08-29 2019-11-12 重庆华邦胜凯制药有限公司 Gc-ms分离测定对氨基水杨酸中相关杂质的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1602188A (en) * 1977-12-01 1981-11-11 Wellcome Found Hydantoin derivatives
JPS6021941B2 (ja) * 1981-01-28 1985-05-30 株式会社村田製作所 圧電性磁器組成物
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
CN1030196C (zh) * 1989-07-07 1995-11-01 詹森药业有限公司 增强收缩力和舒张力的-二氢咪唑并喹唑啉酮衍生物的制备方法
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
US5043327A (en) * 1989-07-18 1991-08-27 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.

Also Published As

Publication number Publication date
US5516908A (en) 1996-05-14
IL103570A (en) 1996-03-31
HU220608B1 (hu) 2002-03-28
NO300976B1 (no) 1997-08-25
NO941497D0 (xx) 1994-04-25
JPH07500599A (ja) 1995-01-19
HU9401245D0 (en) 1994-08-29
ES2083773T3 (es) 1996-04-16
KR100251895B1 (ko) 2000-09-01
WO1993009118A1 (en) 1993-05-13
PL170749B1 (pl) 1997-01-31
ZA928373B (en) 1994-04-29
AU2908392A (en) 1993-06-07
IL103570A0 (en) 1993-03-15
DE69206820T2 (de) 1996-05-15
HUT66453A (en) 1994-11-28
AU660337B2 (en) 1995-06-22
US5521187A (en) 1996-05-28
CN1072681A (zh) 1993-06-02
DE69206820D1 (de) 1996-01-25
FI942010A (fi) 1994-04-29
TW249234B (xx) 1995-06-11
EP0610372A1 (en) 1994-08-17
CA2121230C (en) 2003-03-11
EP0541153A1 (en) 1993-05-12
NZ244779A (en) 1994-10-26
JP3488922B2 (ja) 2004-01-19
CN1041726C (zh) 1999-01-20
CA2121230A1 (en) 1993-05-13
GR3018909T3 (en) 1996-05-31
EP0610372B1 (en) 1995-12-13
PH31245A (en) 1998-06-18
ATE131479T1 (de) 1995-12-15
MX9206258A (es) 1993-04-01
US5541325A (en) 1996-07-30
DK0610372T3 (da) 1996-01-29
NO941497L (no) 1994-04-25
RU2127273C1 (ru) 1999-03-10
FI942010A0 (fi) 1994-04-29

Similar Documents

Publication Publication Date Title
FI105548B (fi) Menetelmä farmaseuttisesti aktiivisten 1,3-dihydro-2H-imidatso(4,5-b)kinolin-2-onien valmistamiseksi
FI83316B (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva 1,3-dihydro-2h-imidazo/4,5-b/kinolin-2-onderivat.
US5021443A (en) Noval benzimidazole and azabenzimiazole derivatives which are thromboxane receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
US4954498A (en) Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use
SK22099A3 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JP2002542245A (ja) 置換イミダゾール、それらの製造および使用
JP2005519046A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのアザインドリルアルキルアミン誘導体
JPH06145170A (ja) ヘテロ環式化合物、その製法及びこれを含有する高血圧及びうつ血性心不全治療用医薬組成物
US5063237A (en) 1,4-dihydro-2-(4-[benzimidazol-l-yl]phenyl)-pyridines as platelet activating factor antagonists
JP3243733B2 (ja) 新規イソキノリン誘導体
SK12222003A3 (sk) Beta-karbolínové deriváty, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitia proti depresii a úzkosti
JPH0631221B2 (ja) ジヒドロピリジン抗アレルギー剤
JPS59101467A (ja) 6,7−ジヒドロ−8−(イミダゾ−ル−1−イル)−5−メチル−1−オキソ−1H,5H−ベンゾ〔ij〕キノリジン−2−カルボン酸およびその誘導体
US5026712A (en) Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents
CA1338599C (en) Imidazole derivatives
DE69214113T2 (de) Neue Pyrrolidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
JPH07242666A (ja) 複素環化合物
JP2002541145A (ja) アリールおよびヘテロアリール縮合アミノアルキル−イミダゾール誘導体:ブラジキニンb2受容体選択性モジュレータ
US5149814A (en) Alkyl 2-benzylidene-4-(2-alkylimidazopyrid-1-yl) benzoylacetate esters as intermediate compounds
US5070205A (en) Alkyl 2-benzylidene-4-(benzimidazol-1-yl) benzoylacetate esters as intermediates
JP2849123B2 (ja) 四置換チオフェン及びその製造方法
US5171858A (en) Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines
EP0462986A1 (en) IMIDAZOPYRIMIDINE ANTIALLERGY AGENTS.
NO893611L (no) Fremstilling av imidazokinolinonderivater.

Legal Events

Date Code Title Description
MA Patent expired